Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AS1409 |
Synonyms | |
Therapy Description |
AS1409 is a fusion protein comprising BC1 and interleukin-12 (IL-12), which allows recognition of the extra-domain B(ED-B) fibronectin isoform present in tumor cells and directly delivers IL-12 to the tumor thereby stimulating an immunological response (PMID: 21447719). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AS1409 | AS1409 is a fusion protein comprising BC1 and interleukin-12 (IL-12), which allows recognition of the extra-domain B(ED-B) fibronectin isoform present in tumor cells and directly delivers IL-12 to the tumor thereby stimulating an immunological response (PMID: 21447719). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | renal cell carcinoma | not applicable | AS1409 | Phase I | Actionable | In a Phase I trial, AS1409 treatment in patients with either melanoma or renal cell carcinoma resulted in stable disease in 46% (6/13) of patients (PMID: 21447719). | 21447719 |
Unknown unknown | melanoma | not applicable | AS1409 | Phase I | Actionable | In a Phase I trial, AS1409 treatment in patients with either melanoma or renal cell carcinoma resulted in stable disease in 46% (6/13) of patients and in two patients with melanoma, one demonstrated a partial response while another showed tumor shrinkage, which lasted beyond 12 months (PMID: 21447719). | 21447719 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|